Tag: HempSmart CBD Product Line

By Steven M. Smith, Inspirational Technologies | PAiNT Research

For years, CBD has lived in a strange and often uncomfortable space — legal, but not fully understood; widely available, but inconsistently regulated; embraced by millions, yet treated with suspicion by institutions that didn’t know what to make of it. The 2018 Farm Bill opened the door to a new era, but it also opened the floodgates to confusion, opportunism, and a marketplace that quickly outgrew its guardrails.

Today, as companies like Square announce sweeping changes that will remove CBD and hemp‑derived products from their platforms, many businesses feel like they’re being forced back to Square One. But maybe that’s exactly where we need to be — not as a setback, but as a reset.

Because CBD is changing. And despite the disruption, it’s changing for the better.

The First Square: Chaos, Confusion, and the Gas‑Station Era

When hemp was legalized in 2018, the intention was clear: allow farmers to grow a crop with enormous therapeutic potential and give consumers access to non‑intoxicating cannabinoids like CBD. But the law didn’t come with the regulatory structure needed to protect consumers or guide businesses.

The result was predictable:

• CBD in gas stations

• CBD with no testing

• CBD with no CBD in it

• CBD marketed as a cure‑all

• CBD companies making illegal medical claims

• CBD investors losing millions as the market cannibalized itself

I lived through that era personally. I watched my wife go from 20 years of chronic pain to peaceful sleep within 30 minutes of taking her first CBD capsule in a California hotel room. I saw CBD work — not as a trend, not as hype, but as a real therapeutic tool.

But I also watched the industry collapse under the weight of its own immaturity. Investors called me daily in late 2018 and early 2019 as stocks fell from $5 to under $1. Companies with 22 billion shares outstanding became shells of their former promise. The science didn’t fail — the system did.

Square’s Announcement: A Shock, But Not a Surprise

Square’s recent notice — informing CBD businesses that accounts will be closed in November 2026 due to federal law changes — feels like déjà vu. Another disruption. Another regulatory shift. Another moment where legitimate CBD businesses are forced to adapt while bad actors seem to slip through cracks.

But this time, the landscape is different.

This isn’t the wild west of 2018. This is the beginning of a new regulatory era.

Square’s decision isn’t arbitrary. It’s a response to federal changes that aim to finally define what hemp‑derived products are legal, how they must be tested, and how they can be sold. For years, the FDA has warned companies about mislabeled products, illegal claims, and unsafe formulations. Now, the federal government is stepping in with clearer definitions and stricter boundaries.

It’s disruptive — yes. But it’s also overdue.

Why This Reset Matters

For CBD to reach its full potential, the industry needs:

• Clear federal definitions

• Uniform testing standards

• Accurate labeling requirements

• Restrictions on intoxicating hemp derivatives

• Real enforcement against snake‑oil products

These changes don’t hurt legitimate CBD companies — they protect them.

They protect consumers. They protect science. They protect the future of cannabinoid therapeutics.

The companies that built their businesses on quality, transparency, and evidence‑based formulations will survive this transition. The ones that built their businesses on loopholes will not.

That’s not a setback. That’s progress.

Starting From Square One — Again, But Smarter

The phrase “Back to Square One” usually implies failure. But in this industry, it means something different. It means returning to the foundation — the science, the safety, the purpose — and rebuilding with the knowledge we didn’t have in 2018.

We’re not starting over. We’re starting smarter.

CBD is changing:

• From unregulated to regulated

• From misunderstood to medically studied

• From gas‑station novelty to therapeutic tool

• From hype to evidence

• From chaos to clarity

The next era of CBD won’t be defined by stock prices, loopholes, or overnight fortunes. It will be defined by legitimacy — the kind that comes from research, responsible manufacturing, and regulatory alignment.

The Future Is Still Bright — Because the Need Is Still Real

My wife’s pain relief wasn’t a fluke. Millions of people have found comfort, sleep, mobility, and peace through CBD. That demand isn’t going away. The science isn’t going away. The therapeutic potential isn’t going away.

What is going away is the noise.

And that’s a good thing.

Square’s announcement may feel like a setback, but it’s actually a sign that CBD is entering a more mature, stable, and credible phase. The industry is being asked to evolve — and the companies are complying.

The Companies That Built on Quality Will Lead the Next Era

The companies that survive this transition will be the ones that always operated with integrity — the ones that tested their products, labeled them accurately, avoided illegal medical claims, and respected the science. These companies aren’t afraid of regulation; they’ve been waiting for it.

Because real CBD — the kind that helped my wife sleep peacefully for the first time in twenty years — deserves real oversight.

The FDA has spent years documenting the problems: mislabeled products, contaminants, unproven claims, and formulations that never should have reached consumers. The agency’s public health focus has been consistent: CBD has potential, but the marketplace must mature before that potential can be fully realized.

Now, with federal law tightening definitions and platforms like Square adjusting their policies, the industry is finally being pushed toward that maturity.

This isn’t the end of CBD. It’s the end of CBD’s adolescence.

Why “Square One” Is Exactly Where We Need To Be

Starting from Square One doesn’t mean starting over. It means returning to the foundation — the science, the safety, the purpose — and rebuilding with the clarity we didn’t have in 2018.

Square One is where:

• Regulation replaces chaos

• Science replaces speculation

• Quality replaces quantity

• Therapeutic value replaces marketing hype

• Trust replaces confusion

Square One is where CBD becomes what it was always meant to be: a legitimate therapeutic tool supported by research, protected by regulation, and delivered by companies that care about more than profit.

Square One is where consumers finally get what they thought they were buying all along.

Square One is where the industry grows up.

CBD Is Changing — And This Time, It’s Changing for the Better

The next era of CBD will not be defined by gas‑station bottles, penny stocks, or overnight fortunes. It will be defined by:

• Clear federal definitions of hemp‑derived cannabinoids

• Uniform testing and safety standards

• Accurate labeling and dosage requirements

• Restrictions on intoxicating derivatives

• Real enforcement against bad actors

• A marketplace that rewards legitimacy, not loopholes

This is the era where CBD becomes part of mainstream therapeutic conversation — not because of hype, but because of evidence.

This is the era where companies like Inspirational Technologies and PAiNT Research can finally operate in a landscape that values science, safety, and transparency.

This is the era where consumers can trust what they’re buying.

This is the era where CBD fulfills the promise it showed in a California hotel room, when one capsule gave my wife the first peaceful sleep she’d had in twenty years.

Square One Isn’t a Setback — It’s a Starting Line

The industry isn’t collapsing. It’s recalibrating.

CBD isn’t disappearing. It’s maturing.

And those of us who entered this field because we saw real human benefit — not because we saw dollar signs — will be the ones who carry it forward.

Square One is not a punishment. Square One is a chance to do it right.

And this time, we will.

Steven’s Message CBD changed my life long before it became an industry. It helped my wife sleep peacefully for the first time in twenty years. It helped my family when prescription options failed. It showed me that natural therapeutics could do what traditional medicine sometimes could not.

But the industry that grew around CBD wasn’t built with the same care. It became chaotic, unregulated, and flooded with products that didn’t honor the science or the people who depended on it. Today, as federal law shifts and platforms like Square prepare to remove CBD from their systems, we are being pushed back to Square One — and that’s exactly where we need to be.

Square One is not a setback. It’s a reset. It’s a chance to rebuild CBD’s reputation with clarity, regulation, and integrity. It’s a chance to return to the reason we started: helping people.

CBD is changing — and this time, it’s changing for the better.